CTRI/2022/10/046723尚未招募2 期
A Double blind, Randomized, Placebo-controlled, Parallel Clinical Trial to Evaluate the Clinical Efficacy and Safety of Vaginal Probiotic Capsule (LABTHERA-001) in patients with Bacterial Vaginosis
Atogen Co., Ltd.0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Non-pregnant, non-breastfeeding females between the ages of 20 and 45 years, inclusive willing to participate in study and provide written informed consent.
- •2. Women of childbearing potential must agree to practice reliable contraception for the 28-day period before enrollment through 30 days following treatment.
- •3. Agree to abstain from sexual intercourse 24 hours before each visit and 6 hours after IP insertion and agrees to follow medically acceptable method of contraception.
- •4. Presenting with signs of Bacterial Vaginosis (as per Amsel Criteria).
- •5. Vaginal specimen should have a Nugent score of greater than or equal to 4
- •6. Women who are currently not menstruating or expected not to have menstruation within 17 days from screening
- •7. Able to understand and comply with planned study procedures
- •8. Willing to abstain from insertion of tampons, douches, or other intravaginal medications or objects during study
- •9. Negative serum or urine pregnancy test
- •10. Provide written informed consent before initiation of any study procedures and be available for all study visits
- •11. No known history of HIV
- •12. Have a refrigerator to store the investigational product
排除标准
- •1)Potential participants who are pregnant or breastfeeding, or if of child-bearing potential unwilling to practice acceptable means of birth control or abstinence during the study
- •2)Patients with vaginal, vulvar, or genitourinary condition that, according to the Investigators
- •14)Any other condition that in the opinion of the investigator does not justify the patientâ??s participation in the study
- •judgement, may confound the interpretation of clinical response based on Liquid Based Cytology
- •3)Patients with a history of regional enteritis, ulcerative colitis, or a history of C. difficile associated diarrhea
- •4)Patients with known current drug or alcohol abuse that could impact study compliance
- •5)Mixed vaginal infections, including bacterial vaginosis and trichomoniasis or coexistent infections with genital herpes and cervicitis based on Liquid Based Cytology
- •6)Self-reported abnormal Papanicolaou smear (grade 3 or more) in the preceding 12 months
- •7)History of diabetes mellitus
- •8)Immunocompromised patients, including those with human immunodeficiency virus seropositivity or with clinically diagnosed acquired immunodeficiency syndrome or its related complex as per HIV test
- •9)Patients who had taken oral or intravenous antifungal agents within 4weeks or used topical vaginal antifungal drugs within 1 week before enrollment
- •10)Terminally ill patients or patients with severe cardiac (creatine kinase values >3 X upper limit of normal laboratory values), hepatic (AST, ALT values >3 X upper limit of normal laboratory values) renal (creatinine > 2mg/dl) or history of cerebrovascular disease, malignancy, chronic uncontrolled systemic disease e.g., hypertension, collagen disorders, etc. or any other serious medical illness.
- •11)Patients with known sensitivity to any of the active or inactive ingredients in the study drug
- •12)Patients with a history of any severe acute or chronic medical or psychiatric condition or laboratory abnormality that could increase the risk associated with trial participation or study treatment administration or could interfere with the interpretation of trial results and, in the judgment of the Investigator, would make the patient inappropriate for entry into the trial.
- •13)Patients who have participated in a new drug study in the past 3 months
研究者
相似试验
招募中
不适用
Multicenter clinical study of the efficacy and safety of the Ongyeong-tang(OKT) for Coldness of Feet(Cold Hypersensitivity in Feet)KCT0003723Sangji University Oriental Medical Center112
未知
2 期
A Double-blind, Placebo-controlled, Randomised, Parallel-group, Phase II, Multi-centre Study to Assess the Efficacy, Safety and Tolerability of 4 Twice Daily Doses and 2 Once Daily Doses of AZD1981 Given as Tablets During 12 Weeks in Asthmatic PatientsAsthmaJPRN-jRCT2080221485AstraZeneca
进行中（未招募）
不适用
A Double-blind, Placebo-controlled, Randomized, Parallel-group Multicenter Study of Mometasone Furoate Nasal Spray on Sleep Disturbances and Daytime Somnolence in Subjects with Symptomatic Seasonal Allergic RhinitisSeasonal Allergic RhinitisEUCTR2005-004464-24-NLIntegrated Therapeutics Group, Inc372
进行中（未招募）
不适用
A Double-blind, Placebo-controlled, Randomized, Parallel-group Multicenter Study of Mometasone Furoate Nasal Spray on Sleep Disturbances and Daytime Somnolence in Subjects with Symptomatic Seasonal Allergic RhinitisSeasonal Allergic RhinitisEUCTR2005-004464-24-DEIntegrated Therapeutics Group, Inc372
进行中（未招募）
1 期
A Double-blind, Placebo-controlled, Randomized, Parallel-group Multicenter Study of Mometasone Furoate Nasal Spray on Sleep Disturbances and Daytime Somnolence in Subjects with Symptomatic Seasonal Allergic RhinitisEUCTR2005-004464-24-BEIntegrated Therapeutics Group, Inc372